首页 | 本学科首页   官方微博 | 高级检索  
检索        


A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men
Authors:Xiaoling Lin  Lianxi Qu  Zhuo Chen  Chuanliang Xu  Dingwei Ye  Qiang Shao  Xiang Wang  Jun Qi  Zhiwen Chen  Fangjian Zhou  Meilin Wang  Zhong Wang  Dalin He  Denglong Wu  Xin Gao  Jianlin Yuan  Gongxian Wang  Yong Xu  Guozeng Wang  Pei Dong  Yang Jiao  Jin Yang  Jun Ou‐Yang  Haowen Jiang  Yao Zhu  Shancheng Ren  Zhengdong Zhang  Changjun Yin  Qijun Wu  Ying Zheng  Aubrey R Turner  Sha Tao  Rong Na  Qiang Ding  Daru Lu  Rong Shi  Jielin Sun  Fang Liu  S Lilly Zheng  Zengnan Mo  Yinghao Sun  Jianfeng Xu
Institution:1. Fudan‐VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China;2. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China;3. Center for Cancer Genomics, Wake Forest University School of Medicine, Winston‐Salem, North Carolina;4. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China;5. Department of Urology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;6. Department of Urology, Suzhou Municipal Hospital, Suzhou, PR China;7. Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China;8. Urology of Institute of PLA, Southwest Hospital, Third Military Medical University, Chongqing, China;9. State Key Laboratory of Oncology in Southern China, Guangzhou, China;10. Department of Urology, Cancer Center, Sun Yat‐Sen University, Guangzhou, China;11. Department of Molecular & Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;12. Department of Urology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China;13. Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China;14. Department of Urology, Tongji Hospital, Tongji University, Shanghai, PR China;15. Department of Urology, The Third Affiliated Hospital, Sun Yat‐sen University, Guangzhou, PR China;16. Department of Urology, Xijing Hospital, Forth Military Medical University, Xi'an, Shaanxi Province, PR China;17. Department of Urology, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China;18. Department of Urology, Second Hospital of TianJin Medical University, TianJin Institute of Urology, Tianjin, China;19. Department of Urology, Pudong Gongli Hospital, Shanghai, PR China;20. Department of Cell Biology, Third Military Medical University, Chongqing, China;21. Department of Urology, First People's Hospital, Suzhou University, Suzhou, PR China;22. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;23. State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;24. Shanghai Center for Disease Control and Prevention, Shanghai, China;25. State Key Laboratory of Genetic Engineering, Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, PR China;26. School of Public Health, Shanghai Jiaotong University, Shanghai, PR China;27. Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, PR China;28. Department of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, PR China
Abstract:
Keywords:HOXB13  G135E  G84E  prostate cancer  Chinese  rare mutation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号